Talk:Fenofibrate

Untitled
I'm taking Tricor 145mg and it keeps me from getting any gout attacks. I was regulating my gout with diet and Allopurinol 100mg and attacks with Indomethacin50mg. After starting with Tricor I stopped the other medications and as long as I take the Tricor I don't get any signs of gout. —Preceding unsigned comment added by D1hamby (talk • contribs) 11:53, 20 June 2008 (UTC)

"Although the hypothesized pathway of action for fenofibrate does not involve adiponectin, two placebo-controlled studies have found that short trials of fenofibrate significantly increased circulating adiponectin [18,19], while two other short trials of fenofibrate found non-significant increases in adiponectin [20,21]."  --Dan Wylie-Sears 2 (talk) 10:00, 16 September 2009 (UTC)

This page is immensely confusing, especially the introduction. Can we reduce it to layman's terms? 76.252.63.179 (talk) 17:07, 7 February 2010 (UTC)

other studies
most of the studies listed in this article point to the positive effects of TriCor. What about the 2003 study that showed that TriCor had NO effect for diabetics, and the new 2010 (funded by the National Heart, Lung and Blood Institute) in which 5,500 patients with diabetes showed no statistical differences in rates of heart attack, stroke, or death as compared with a placebo (the "Accord" trial)? —Preceding unsigned comment added by 74.179.113.6 (talk) 19:34, 2 April 2010 (UTC)

selective amyloid raising agent
I read that fenofibrate is used in pharmacological studies as an "selective amyloid raising agent". Is that an important use for fenofibrate? Crampino (talk) 17:52, 3 December 2010 (UTC)Crampino

FDA MedWatch announcement 9-Nov-2011
"Trilipix (fenofibric acid): Drug Safety Communication - Label Change

AUDIENCE: Family Practice, Cardiology, Pharmacy

ISSUE: FDA notified healthcare professionals the cholesterol-lowering medicine Trilipix (fenofibric acid) may not lower a patient's risk of having a heart attack or stroke. FDA reviewed the data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid trial. The ACCORD Lipid trial found no significant difference in the risk of experiencing a major adverse cardiac event between the group treated with fenofibrate plus simvastatin compared with simvastatin alone.

Information from the trial has been added to the Important Limitations of Use and Warnings and Precautions sections of the Trilipix physician label and to the patient Medication Guide.

BACKGROUND: Trilipix (fenofibric acid) was approved by FDA in 2008 to treat cholesterol in the blood by lowering the total amount of triglycerides and low-density lipoprotein (LDL) cholesterol, and increasing the high-density lipoprotein (HDL) cholesterol.

RECOMMENDATION: Fenofibrate at a dose equivalent to 135 mg of Trilipix was not shown to reduce coronary heart disease morbidity and mortality in patients in two large randomized controlled trials of patients with type 2 diabetes mellitus; healthcare professionals should consider the benefits and risks of Trilipix when deciding to prescribe the drug to patients, and counsel patients about those benefits and risks." If anyone wishes to make a reference to that announcement in the article, it's at http://links.govdelivery.com/track?type=click&enid=ZWFzPTEmbWFpbGluZ2lkPTIwMTExMTA5LjM4NDk5NjEmbWVzc2FnZWlkPU1EQi1QUkQtQlVMLTIwMTExMTA5LjM4NDk5NjEmZGF0YWJhc2VpZD0xMDAxJnNlcmlhbD0xNjc4MDA3OCZlbWFpbGlkPXN0ZXBoZW4ucC52aWxsYW5vQGdtYWlsLmNvbSZ1c2VyaWQ9c3RlcGhlbi5wLnZpbGxhbm9AZ21haWwuY29tJmZsPSZleHRyYT1NdWx0aXZhcmlhdGVJZD0mJiY=&&&102&&&http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm279185.htm Wzrd1 (talk) 15:51, 9 November 2011 (UTC)

Plagiarism
The unquoted sentence "In particular, ACCORD-Lipid trial, in our view, supports the addition of fenofibrate to statin therapy" is a plagiarism from http://www.ncbi.nlm.nih.gov/pubmed/21102326 - Robert Badgett 14:14, 10 November 2011 (UTC)

Abbott Laboratories
Please accept the edits to this page (February 14, 2013). My name is Scott Stoffel, and I work at Abbott Laboratories in Corporate Public Affairs, and the edits I am providing are all factual, based upon review of the page with Abbott Laboratories scientists who have expertise in this area. If you have questions, please do not hesitate to access my contact information, found here: http://abbott.com/news-media/contacts.htm — Preceding unsigned comment added by ScottStoffelAbbott (talk • contribs) 18:31, 14 February 2013 (UTC) ScottStoffelAbbott (talk) 20:35, 15 February 2013 (UTC)

RE: Scott Stoffel/Abbott edit. You removed the following statement: "Fenofibrate increases the serum level of statins. Therefore, a lower dose of statin is generally necessary." If this is a recognized action of the drug(s) involved, and is germane to the article, why was it taken out? I will find the referenced document for that statement and insert it back into the paragraph. I happen to be on both meds and did have to cut the statin back after liver function - AST etc., deemed it prudent. So I know about this from personal experience. You should not casually disrupt the exchange of important information on this site. I know doctors in this day and age go strait to WP for summery data and you should not impede the resource. Any positive contribution that is neutral to the subject is welcome however.99.32.160.175 (talk) 06:02, 23 January 2014 (UTC)

Why does "Procetofen" redirect here?
Is it a trade name for this drug? It is not mentioned within the article. 86.179.191.90 (talk) 01:23, 8 February 2015 (UTC)
 * Not a trade name, but the first common name by which fenofibrate was known (much as "acetaminophen" and "paracetamol" refer to the same drug). The article is a bit of a mess, but I suppose this warrants mention in a brief "History" section. Fvasconcellos (t·c) 02:02, 8 February 2015 (UTC)

Fenofibric acid
Fenofibrate is the isopropyl ester of Fenofibric acid. but Fenofibric acid redirects to here. — Preceding unsigned comment added by 79.74.30.197 (talk) 18:22, 3 June 2016 (UTC)